S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Novo Nordisk Arms Wegovy to Be a Triple Threat
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Citi’s Results Say This About The Stock Market
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Novo Nordisk Arms Wegovy to Be a Triple Threat
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Citi’s Results Say This About The Stock Market
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Novo Nordisk Arms Wegovy to Be a Triple Threat
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Citi’s Results Say This About The Stock Market
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Novo Nordisk Arms Wegovy to Be a Triple Threat
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Citi’s Results Say This About The Stock Market
NASDAQ:BEAM

Beam Therapeutics (BEAM) Stock Price, News & Analysis

$25.93
-1.34 (-4.91%)
(As of 04/12/2024 08:51 PM ET)
Today's Range
$25.52
$26.99
50-Day Range
$25.93
$45.07
52-Week Range
$16.95
$49.50
Volume
1.30 million shs
Average Volume
1.38 million shs
Market Capitalization
$2.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Beam Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
58.1% Upside
$41.00 Price Target
Short Interest
Healthy
16.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Beam Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$4.73 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.53) to ($5.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

362nd out of 928 stocks

Biological Products, Except Diagnostic Industry

52nd out of 156 stocks

BEAM stock logo

About Beam Therapeutics Stock (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock Price History

BEAM Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
NASDAQ:BEAM (Beam Therapeutics)
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down to $29.32
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Poseida Therapeutics (PSTX) Gets a Buy from William Blair
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/15/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
436
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$57.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+58.1%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-132,530,000.00
Pretax Margin
-34.72%

Debt

Sales & Book Value

Annual Sales
$377.71 million
Book Value
$12.04 per share

Miscellaneous

Free Float
78,065,000
Market Cap
$2.12 billion
Optionable
Optionable
Beta
1.77

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

BEAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price target for 2024?

13 brokers have issued 12 month price targets for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $57.00. On average, they predict the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 58.1% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2024?

Beam Therapeutics' stock was trading at $27.22 on January 1st, 2024. Since then, BEAM shares have decreased by 4.7% and is now trading at $25.93.
View the best growth stocks for 2024 here
.

Are investors shorting Beam Therapeutics?

Beam Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 13,450,000 shares, a drop of 6.1% from the March 15th total of 14,320,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is presently 9.7 days.
View Beam Therapeutics' Short Interest
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its earnings results on Tuesday, February, 27th. The company reported $1.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $2.42. The business had revenue of $316.20 million for the quarter, compared to analyst estimates of $34.16 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 35.09%. The firm's revenue was up 1481.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.54) EPS.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

Beam Therapeutics (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include DLK Investment Management LLC (0.01%) and Riverview Trust Co (0.00%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends
.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
This page (NASDAQ:BEAM) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners